Information Provided By: 
Fly News Breaks for June 21, 2018
HRTX, PCRX
Jun 21, 2018 | 15:42 EDT
BMO Capital analyst Gary Nachman said the newly released Phase 2b data for Heron Therapeutics' (HRTX) HTX-011 in post-surgical pain support a "very solid profile" for the drug, which he thinks will eventually likely be a "viable competitor" to Pacira's (PCRX) Exparel. Given the new data, a more cautious long-term outlook for Exparel may be warranted, contends Nachman, who keeps a Market Perform rating on Pacira shares. In late day trading, Heron shares are up 29% to $39.70, while Pacira has fallen 12% to $34.98.
News For PCRX;HRTX From the Last 2 Days
